In addition to immunotherapy, BRAF and MEK inhibitors (dabrafenib + trametinib) are approved as adjuvant treatment for patients with stage III BRAF-mutant melanoma, based on the COMBI-AD trial [60]. Here, MAP2K7 is linked to melanoma.